{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:52:16Z","timestamp":1791895936215,"version":"4.3.4"},"reference-count":228,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Aspects of Medicine"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.mam.2025.101359","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T10:45:01Z","timestamp":1741085101000},"page":"101359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Targeting and engineering biomarkers for prostate cancer therapy"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4117-3923","authenticated-orcid":false,"given":"Dhirodatta","family":"Senapati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhabani Shankar","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyanarayan","family":"Senapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal C.","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subrat Kumar","family":"Bhattamisra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mam.2025.101359_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/8029721","article-title":"Development of MicroRNAs as potential therapeutics against cancer","volume":"2020","author":"Abd-Aziz","year":"2020","journal-title":"J Oncol"},{"issue":"7675","key":"10.1016\/j.mam.2025.101359_bib2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR\u2013Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/acschembio.8b00807","article-title":"Selective small-molecule targeting of a triple helix encoded by the long noncoding RNA, MALAT1","volume":"14","author":"Abulwerdi","year":"2019","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib4","first-page":"11","volume":"379","author":"Adams","year":"2018","journal-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis"},{"issue":"10","key":"10.1016\/j.mam.2025.101359_bib5","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1039\/D0BM00015A","article-title":"Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy","volume":"8","author":"Ahir","year":"2020","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s41021-022-00252-3","article-title":"Targeting the MALAT1 gene with the CRISPR\/Cas9 technique in prostate cancer","volume":"44","author":"Ahmadi-Balootaki","year":"2022","journal-title":"Gene Environ."},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nbt1402","article-title":"A combinatorial library of lipid-like materials for delivery of RNAi therapeutics","volume":"26","author":"Akinc","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mam.2025.101359_bib8","first-page":"645","article-title":"Circular RNAs: novel actors of Wnt signaling pathway in lung cancer progression","volume":"22","author":"Alimohammadi","year":"2023","journal-title":"EXCLI Journal"},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib9","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nm1345","article-title":"Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology","volume":"12","author":"Alter","year":"2006","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib10","volume":"2020","author":"Ambrozkiewicz","year":"2020","journal-title":"Challenges in Cancer Biomarker Discovery Exemplified by the Identification of Diagnostic MicroRNAs in Prostate Tissues"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib11","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bcp.2013.08.026","article-title":"Biomarkers in pharmacology and drug discovery","volume":"87","author":"Anderson","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"20","key":"10.1016\/j.mam.2025.101359_bib12","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.2217\/fon-2017-0078","article-title":"Serum metabolomics can predict the outcome of first systematic transrectal prostate biopsy in patients with PSA <10 ng\/ml","volume":"13","author":"Andras","year":"2017","journal-title":"Future Oncol."},{"issue":"4","key":"10.1016\/j.mam.2025.101359_bib13","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1158\/2159-8290.CD-17-0937","article-title":"Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer","volume":"8","author":"Annala","year":"2018","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib14","volume":"4","author":"Anselmo","year":"2019","journal-title":"Nanoparticles in the clinic: An update"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib15","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1186\/s12864-015-2086-z","article-title":"DECKO: single-oligo, dual-CRISPR deletion of genomic elements including long non-coding RNAs","volume":"16","author":"Aparicio-Prat","year":"2015","journal-title":"BMC Genom."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib16","first-page":"46","article-title":"Iron oxide nanoparticles for biomedical applications: a Perspective on synthesis","volume":"7","author":"Arias","year":"2018","journal-title":"Drugs, Antimicrobial Activity, and Toxicity."},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.molmed.2018.01.001","article-title":"Therapeutic targeting of long non-coding RNAs in cancer","volume":"24","author":"Arun","year":"2018","journal-title":"Trends Mol. Med."},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib18","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/brv.12413","article-title":"The diverse origins of circulating cell-free DNA in the human body: a critical re-evaluation of the literature","volume":"93","author":"Aucamp","year":"2018","journal-title":"Biol Rev Camb Philos Soc"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41746-020-0274-y","article-title":"Deep learning-enabled point-of-care sensing using multiplexed paper-based sensors","volume":"3","author":"Ballard","year":"2020","journal-title":"npj Digital Medicine"},{"key":"10.1016\/j.mam.2025.101359_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.bios.2015.03.006","article-title":"Portable smartphone quantitation of prostate specific antigen (PSA) in a fluoropolymer microfluidic device","volume":"70","author":"Barbosa","year":"2015","journal-title":"Biosens. Bioelectron."},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib21","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0090-4295(98)00366-5","article-title":"Most prostate cancers missed by raising the upper limit of normal prostate-specific antigen for men in their sixties are clinically significant","volume":"52","author":"Bassler","year":"1998","journal-title":"Urology"},{"issue":"17","key":"10.1016\/j.mam.2025.101359_bib22","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.4155\/fmc.14.116","article-title":"miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents","volume":"6","author":"Baumann","year":"2014","journal-title":"Future Med. Chem."},{"issue":"7","key":"10.1016\/j.mam.2025.101359_bib23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nbt.2283","article-title":"From single cells to deep phenotypes in cancer","volume":"30","author":"Bendall","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mam.2025.101359_bib24","first-page":"81","volume":"57","author":"Bennett","year":"2017","journal-title":"Pharmacology of Antisense Drugs. 57"},{"issue":"4","key":"10.1016\/j.mam.2025.101359_bib25","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.xphs.2018.11.022","article-title":"The potential of exosomes from cow milk for oral delivery","volume":"108","author":"Betker","year":"2019","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jconrel.2004.11.011","article-title":"Long-circulating DNA-complexed biodegradable multiblock copolymers for gene delivery: degradation profiles and evidence of dysopsonization","volume":"103","author":"Bikram","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/j.mam.2025.101359_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.actbio.2014.09.020","article-title":"Degradable polymer-coated gold nanoparticles for co-delivery of DNA and siRNA","volume":"11","author":"Bishop","year":"2015","journal-title":"Acta Biomater."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib28","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.devcel.2015.09.017","article-title":"Morpholinos: antisense and sensibility","volume":"35","author":"Blum","year":"2015","journal-title":"Dev. Cell"},{"issue":"10","key":"10.1016\/j.mam.2025.101359_bib29","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/14737159.2019.1675515","article-title":"Clinical utility of emerging biomarkers in prostate cancer liquid biopsies","volume":"20","author":"Boerrigter","year":"2020","journal-title":"Expert Rev. Mol. Diagn"},{"issue":"11","key":"10.1016\/j.mam.2025.101359_bib31","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.1880","article-title":"The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities","volume":"14","author":"Bonci","year":"2008","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.mam.2025.101359_bib32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/ng.3315","article-title":"Spatial genomic heterogeneity within localized, multifocal prostate cancer","volume":"47","author":"Boutros","year":"2015","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.mam.2025.101359_bib33","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1093\/nar\/gkp106","article-title":"A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity","volume":"37","author":"Bramsen","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib34","first-page":"229","volume":"74","author":"Bray","year":"2024","journal-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries"},{"issue":"49","key":"10.1016\/j.mam.2025.101359_bib35","doi-asserted-by":"crossref","first-page":"14013","DOI":"10.1073\/pnas.1614759113","article-title":"Methyltransferase-like protein 16 binds the 3'-terminal triple helix of MALAT1 long noncoding RNA","volume":"113","author":"Brown","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib37","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrclinonc.2010.43","article-title":"Biomarkers and surrogate end points\u2014the challenge of statistical validation","volume":"7","author":"Buyse","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.mam.2025.101359_bib39","doi-asserted-by":"crossref","first-page":"7390","DOI":"10.1158\/0008-5472.CAN-06-0800","article-title":"MicroRNA-cancer connection: the beginning of a new tale","volume":"66","author":"Calin","year":"2006","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib40","first-page":"730","volume":"32","author":"Canick","year":"2012","journal-title":"DNA sequencing of maternal plasma to identify Down syndrome and other trisomies in multiple gestations"},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib41","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0022-5347(17)35233-3","article-title":"Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men","volume":"151","author":"Catalona","year":"1994","journal-title":"J. Urol."},{"key":"10.1016\/j.mam.2025.101359_bib42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In vivo delivery of miRNAs for cancer therapy: challenges and strategies","volume":"81","author":"Chen","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"12","key":"10.1016\/j.mam.2025.101359_bib43","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1517\/13543780802528609","article-title":"Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin for the treatment of cancer","volume":"17","author":"Chi","year":"2008","journal-title":"Expet Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib44","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol Cell"},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib45","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nn.4280","article-title":"The RNA-binding protein SFPQ orchestrates an RNA regulon to promote axon viability","volume":"19","author":"Cosker","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib46","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/mt.2008.215","article-title":"A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells","volume":"17","author":"Crombez","year":"2009","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/nat.2016.0656","article-title":"Molecular mechanisms of antisense oligonucleotides","volume":"27","author":"Crooke","year":"2017","journal-title":"Nucleic Acid Therapeut."},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.3779","article-title":"Cellular uptake and trafficking of antisense oligonucleotides","volume":"35","author":"Crooke","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.mam.2025.101359_bib49","series-title":"Prostate Cancer","article-title":"Biomarkers of aggressiveness in prostate cancer","author":"Cuvillier","year":"2011"},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib50","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ymeth.2003.11.023","article-title":"Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications","volume":"33","author":"Dalby","year":"2004","journal-title":"Methods"},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib51","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1158\/1078-0432.CCR-09-2167","article-title":"Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents","volume":"16","author":"Dancey","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/s24010037","article-title":"Biomarkers in cancer detection, diagnosis, and prognosis","volume":"24","author":"Das","year":"2023","journal-title":"Sensors (Basel)"},{"issue":"19\u201320","key":"10.1016\/j.mam.2025.101359_bib53","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.cca.2010.05.040","article-title":"Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate metastatic prostate cancer from localized disease","volume":"411","author":"Deligezer","year":"2010","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.mam.2025.101359_bib54","first-page":"2557","volume":"vol. 36","author":"Dhawan","year":"2018"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.gde.2013.01.004","article-title":"miRNA profiling of cancer","volume":"23","author":"Di Leva","year":"2013","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib56","first-page":"347","article-title":"Antisense oligonucleotides: basic concepts and mechanisms","volume":"1","author":"Dias","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"16","key":"10.1016\/j.mam.2025.101359_bib57","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2511","article-title":"Antisense oligonucleotide-mediated knockdown in mammary tumor organoids","volume":"7","author":"Diermeier","year":"2017","journal-title":"Bio-protocol"},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib58","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1021\/acschembio.6b00001","article-title":"Inforna 2.0: a platform for the sequence-based design of small molecules targeting structured RNAs","volume":"11","author":"Disney","year":"2016","journal-title":"ACS Chem. Biol."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib59","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1039\/C5AN01829C","article-title":"Electrochemistry-based approaches to low cost, high sensitivity, automated, multiplexed protein immunoassays for cancer diagnostics","volume":"141","author":"Dixit","year":"2016","journal-title":"Analyst"},{"key":"10.1016\/j.mam.2025.101359_bib60","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.jconrel.2020.04.003","article-title":"Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy","volume":"322","author":"Dong","year":"2020","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib61","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/erm.10.122","article-title":"Progensa\u2122 PCA3 test for prostate cancer","volume":"11","author":"Durand","year":"2011","journal-title":"Expert Rev. Mol. Diagn."},{"issue":"9","key":"10.1016\/j.mam.2025.101359_bib62","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41434-020-0156-6","article-title":"Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy","volume":"27","author":"Dzierlega","year":"2020","journal-title":"Gene Ther."},{"issue":"11\u201312","key":"10.1016\/j.mam.2025.101359_bib63","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jgm.2810","article-title":"Designing a gold nanoparticle-based nanocarrier for microRNA transfection into the prostate and breast cancer cells","volume":"16","author":"Ekin","year":"2014","journal-title":"J. Gene Med."},{"issue":"7189","key":"10.1016\/j.mam.2025.101359_bib64","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nature06783","article-title":"LNA-mediated microRNA silencing in non-human primates","volume":"452","author":"Elm\u00e9n","year":"2008","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib65","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","article-title":"The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (primary): a prospective multicentre study","volume":"80","author":"Emmett","year":"2021","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib66","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2217\/epi.11.90","article-title":"miRNA therapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs","volume":"3","author":"Fabbri","year":"2011","journal-title":"Epigenomics"},{"key":"10.1016\/j.mam.2025.101359_bib67","author":"Fabbri"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib68","doi-asserted-by":"crossref","DOI":"10.1038\/srep38243","article-title":"Prostate cancer patients\u2013negative biopsy controls discrimination by untargeted metabolomics analysis of urine by LC-QTOF: upstream information on other omics","volume":"6","author":"Fern\u00e1ndez-Peralbo","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib69","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/1471-2407-12-507","article-title":"PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling","volume":"12","author":"Ferreira","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.mam.2025.101359_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.736323","article-title":"MicroRNA as an important target for anticancer drug development","volume":"12","author":"Fu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.mam.2025.101359_bib71","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fmed.2015.00064","article-title":"Insights into regulation of the miR-17-92 cluster of miRNAs in cancer","volume":"2","author":"Fuziwara","year":"2015","journal-title":"Front. Med."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2005.01.006","article-title":"The fundamental role of epigenetics in hematopoietic malignancies","volume":"20","author":"Galm","year":"2006","journal-title":"Blood Rev."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000438641","article-title":"The roles of MicroRNA-141 in human cancers: from diagnosis to treatment","volume":"38","author":"Gao","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"issue":"10","key":"10.1016\/j.mam.2025.101359_bib74","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrd3179","article-title":"Targeting microRNAs in cancer: rationale, strategies and challenges","volume":"9","author":"Garzon","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"issue":"11","key":"10.1016\/j.mam.2025.101359_bib75","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrm3679","article-title":"RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts","volume":"14","author":"Geisler","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib76","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10529-021-03085-2","article-title":"Co-delivery of miRNA-15a and miRNA-16-1 using cationic PEGylated niosomes downregulates Bcl-2 and induces apoptosis in prostate cancer cells","volume":"43","author":"Ghaffari","year":"2021","journal-title":"Biotechnol. Lett."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib77","doi-asserted-by":"crossref","first-page":"326","DOI":"10.21037\/tau.2017.03.06","article-title":"Long non-coding RNAs: new frontiers for advancing personalized cancer medicine in prostate cancer","volume":"6","author":"Ghiam","year":"2017","journal-title":"Transl. Androl. Urol."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12868","article-title":"Local microRNA delivery targets Palladin and prevents metastatic breast cancer","volume":"7","author":"Gilam","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib79","doi-asserted-by":"crossref","DOI":"10.3390\/metabo7010009","article-title":"The role of sarcosine, uracil, and kynurenic acid metabolism in urine for diagnosis and progression monitoring of prostate cancer","volume":"7","author":"Gkotsos","year":"2017","journal-title":"Metabolites"},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib80","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0142-9612(00)00203-9","article-title":"Poly(ethylenimine)-mediated gene delivery affects endothelial cell function and viability","volume":"22","author":"Godbey","year":"2001","journal-title":"Biomaterials"},{"issue":"16","key":"10.1016\/j.mam.2025.101359_bib81","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1011367","article-title":"Systemic administration of PRO051 in Duchenne's muscular dystrophy","volume":"364","author":"Goemans","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.mam.2025.101359_bib82","first-page":"5941","article-title":"Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids","volume":"60","author":"Goessl","year":"2000","journal-title":"Cancer Res."},{"issue":"6336","key":"10.1016\/j.mam.2025.101359_bib83","first-page":"438","volume":"356","author":"Gootenberg","year":"2017","journal-title":"Nucleic acid detection with CRISPR-Cas13a\/C2c2"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47189-2","article-title":"Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide","volume":"9","author":"Greene","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.mam.2025.101359_bib85","doi-asserted-by":"crossref","DOI":"10.1177\/1177271920974652","article-title":"Biomarkers: opportunities and challenges for drug development in the current regulatory landscape","volume":"15","author":"Gromova","year":"2020","journal-title":"Biomark. Insights"},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib86","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Group","year":"2001","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.mam.2025.101359_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctarc.2019.100120","article-title":"Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time","volume":"19","author":"Hahn","year":"2019","journal-title":"Cancer Treatment and Research Communications"},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib88","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1734-1140(09)70160-4","article-title":"Polymer-based non-viral gene delivery as a concept for the treatment of cancer","volume":"61","author":"Halama","year":"2009","journal-title":"Pharmacol. Rep."},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib89","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S1734-1140(09)70160-4","article-title":"Polymer-based non-viral gene delivery as a concept for the treatment of cancer","volume":"61","author":"Halama","year":"2009","journal-title":"Pharmacol. Rep."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2016.09.001","article-title":"Biomarkers of outcome in patients with localized prostate cancer treated with radiotherapy","volume":"27","author":"Hall","year":"2017","journal-title":"Semin. Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.mam.2025.101359_bib91","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013243","article-title":"Delivery of oligonucleotide-based therapeutics: challenges and opportunities","volume":"13","author":"Hammond","year":"2021","journal-title":"EMBO Mol. Med."},{"issue":"7187","key":"10.1016\/j.mam.2025.101359_bib92","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nature06916","article-title":"Mining the plasma proteome for cancer biomarkers","volume":"452","author":"Hanash","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib93","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1021\/nl2035354","article-title":"Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer","volume":"12","author":"Hasan","year":"2012","journal-title":"Nano Lett."},{"key":"10.1016\/j.mam.2025.101359_bib94","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/1471-2407-9-461","article-title":"Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma","volume":"9","author":"He","year":"2009","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.mam.2025.101359_bib95","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"10","key":"10.1016\/j.mam.2025.101359_bib96","first-page":"1666","volume":"108","author":"Hsieh","year":"2011","journal-title":"R11, a novel cell-permeable peptide, as an intravesical delivery vehicle"},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib97","doi-asserted-by":"crossref","first-page":"763.e761","DOI":"10.1016\/j.urology.2010.07.526","article-title":"ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program","volume":"77","author":"Isharwal","year":"2011","journal-title":"Urology"},{"issue":"12","key":"10.1016\/j.mam.2025.101359_bib98","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1002\/ijc.28303","article-title":"Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma","volume":"133","author":"Jung","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"49","key":"10.1016\/j.mam.2025.101359_bib99","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics9010021","article-title":"Metabolomics biomarkers of prostate cancer: a systematic review","volume":"9","author":"Kdadra","year":"2019","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib101","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nbt.3765","article-title":"The chemical evolution of oligonucleotide therapies of clinical utility","volume":"35","author":"Khvorova","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"17","key":"10.1016\/j.mam.2025.101359_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174435","article-title":"Recent advances in exosome-based drug delivery for cancer therapy","volume":"13","author":"Kim","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib103","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2020.05.215","article-title":"Therapeutic efficacy of modified anti-miR21 in metastatic prostate cancer","volume":"529","author":"Kim","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib104","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1371\/journal.pbio.0050203","article-title":"Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development","volume":"5","author":"Kloosterman","year":"2007","journal-title":"PLoS Biol."},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib105","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1371\/journal.pbio.0050203","article-title":"Targeted inhibition of miRNA maturation with morpholinos reveals a role for miR-375 in pancreatic islet development","volume":"5","author":"Kloosterman","year":"2007","journal-title":"PLoS Biol."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib106","first-page":"70","article-title":"Screening for lncRNA function","volume":"18","author":"Koch","year":"2017","journal-title":"Nat. Rev. Genet."},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib107","first-page":"2042","volume":"15","author":"Koh","year":"2023","journal-title":"Exosome-Based Drug Delivery: Translation from Bench to Clinic"},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib108","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cell.2018.01.011","article-title":"Functional classification and experimental dissection of long noncoding RNAs","volume":"172","author":"Kopp","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib109","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1074\/jbc.M111.288662","article-title":"Competitive interactions of cancer cells and normal cells via secretory microRNAs","volume":"287","author":"Kosaka","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"15","key":"10.1016\/j.mam.2025.101359_bib110","first-page":"3111","volume":"57","author":"Kumar","year":"1997","journal-title":"Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2"},{"issue":"12","key":"10.1016\/j.mam.2025.101359_bib111","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/pros.23198","article-title":"NMR spectroscopy of filtered serum of prostate cancer: a new frontier in metabolomics","volume":"76","author":"Kumar","year":"2016","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.mam.2025.101359_bib112","doi-asserted-by":"crossref","first-page":"256","DOI":"10.31083\/j.fbl2709256","article-title":"Targeting castration-resistant prostate cancer using mesenchymal stem cell exosomes for therapeutic MicroRNA-let-7c delivery","volume":"27","author":"Kurniawati","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"7","key":"10.1016\/j.mam.2025.101359_bib113","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1089\/hum.2015.069","article-title":"Challenges in CRISPR\/CAS9 delivery: potential roles of nonviral vectors","volume":"26","author":"Li","year":"2015","journal-title":"Hum. Gene Ther."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib114","article-title":"Circular RNA cir-ITCH is a potential therapeutic target for the treatment of castration-resistant","volume":"2020","author":"Li","year":"2020","journal-title":"Prostate Cancer"},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib115","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1172\/JCI112185","article-title":"A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein","volume":"76","author":"Lilja","year":"1985","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.mam.2025.101359_bib116","series-title":"Antisense Drug Technology Principles, Strategies, and Applications","first-page":"848","article-title":"The RNase H mechanism","author":"Lima","year":"2007"},{"issue":"11","key":"10.1016\/j.mam.2025.101359_bib117","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nrd4140","article-title":"MicroRNAs and other non-coding RNAs as targets for anticancer drug development","volume":"12","author":"Ling","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib118","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm.2284","article-title":"The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44","volume":"17","author":"Liu","year":"2011","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.mam.2025.101359_bib119","doi-asserted-by":"crossref","first-page":"6970","DOI":"10.1021\/jacs.9b13159","article-title":"Targeted degradation of the oncogenic MicroRNA 17-92 cluster by structure-targeting ligands","volume":"142","author":"Liu","year":"2020","journal-title":"J. Am. Chem. Soc."},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib120","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/cmdc.200900076","article-title":"PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells","volume":"4","author":"Liu","year":"2009","journal-title":"ChemMedChem"},{"issue":"14","key":"10.1016\/j.mam.2025.101359_bib121","doi-asserted-by":"crossref","first-page":"5624","DOI":"10.1074\/jbc.M116.769034","article-title":"Biallelic insertion of a transcriptional terminator via the CRISPR\/Cas9 system efficiently silences expression of protein-coding and non-coding RNA genes","volume":"292","author":"Liu","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.mam.2025.101359_bib122","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040802","article-title":"Circulating cancer biomarkers","volume":"13","author":"Lokshin","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.mam.2025.101359_bib123","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.omtn.2019.10.015","article-title":"Characterization of a prostate- and prostate cancer-specific circular RNA encoded by the androgen receptor gene","volume":"18","author":"Luo","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib124","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1038\/s41467-019-09784-9","article-title":"LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2\/STAT3 signaling","volume":"10","author":"Luo","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.mam.2025.101359_bib125","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.addr.2020.06.020","article-title":"Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles","volume":"156","author":"Luther","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mam.2025.101359_bib126","volume":"13","author":"Mafi","year":"2023","journal-title":"A spotlight on the interplay between Wnt\/\u03b2-catenin signaling and circular RNAs in hepatocellular carcinoma progression"},{"issue":"9","key":"10.1016\/j.mam.2025.101359_bib127","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.tips.2021.06.001","article-title":"Screening strategies for identifying RNA- and ribonucleoprotein-targeted compounds","volume":"42","author":"Martin","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"issue":"18","key":"10.1016\/j.mam.2025.101359_bib128","first-page":"1697","article-title":"DNA-repair defects and olaparib in metastatic","volume":"373","author":"Mateo","year":"2015","journal-title":"Prostate Cancer"},{"issue":"11","key":"10.1016\/j.mam.2025.101359_bib129","doi-asserted-by":"crossref","first-page":"4394","DOI":"10.1073\/pnas.1014720108","article-title":"Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing","volume":"108","author":"Melo","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.mam.2025.101359_bib130","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nat Rev Methods Primers"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib131","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nature Reviews Methods Primers"},{"issue":"19","key":"10.1016\/j.mam.2025.101359_bib132","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231911502","article-title":"miRNA: a promising therapeutic target in cancer","volume":"23","author":"Menon","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.mam.2025.101359_bib133","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.1016\/S0021-9258(19)85268-7","article-title":"Evaluation of 2\u2018-modified oligonucleotides containing 2\u2018-deoxy gaps as antisense inhibitors of gene expression","volume":"268","author":"Monia","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib134","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1078-0432.CCR-10-2410","article-title":"Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer","volume":"17","author":"Morgan","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib135","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nbt1122","article-title":"Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs","volume":"23","author":"Morrissey","year":"2005","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib136","doi-asserted-by":"crossref","first-page":"4.30.31","DOI":"10.1002\/cpnc.21","article-title":"Using morpholinos to control gene expression","volume":"68","author":"Moulton","year":"2017","journal-title":"Curr Protoc Nucleic Acid Chem"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib137","article-title":"Using Morpholinos to control gene expression","volume":"26","author":"Moulton","year":"2008","journal-title":"Curr Protoc Mol Biol Chapter"},{"issue":"9","key":"10.1016\/j.mam.2025.101359_bib138","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090289","article-title":"miRNA-205 nanoformulation sensitizes prostate cancer cells to chemotherapy","volume":"10","author":"Nagesh","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.mam.2025.101359_bib139","series-title":"Hormone Therapy and Castration Resistance of Prostate Cancer","first-page":"397","article-title":"Gene therapy for prostate cancer: current status and future prospects","author":"Nasu","year":"2018"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib140","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2018.03.028","article-title":"Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology","volume":"75","author":"Nuhn","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.mam.2025.101359_bib141","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA biogenesis, mechanisms of actions, and circulation","volume":"9","author":"O'Brien","year":"2018","journal-title":"Front. Endocrinol."},{"issue":"17","key":"10.1016\/j.mam.2025.101359_bib142","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174492","article-title":"Role of metastasis-related microRNAs in prostate cancer progression and treatment","volume":"13","author":"Oh-Hohenhorst","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.mam.2025.101359_bib143","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.ejca.2008.03.006","article-title":"Prognostic versus predictive value of biomarkers in oncology","volume":"44","author":"Oldenhuis","year":"2008","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib144","first-page":"1034","volume":"7","author":"Olsson","year":"2015","journal-title":"Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease"},{"issue":"21","key":"10.1016\/j.mam.2025.101359_bib145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215491","article-title":"The development of functional non-viral vectors for gene delivery","volume":"20","author":"Patil","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib146","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41565-017-0012-z","article-title":"Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression","volume":"13","author":"Pi","year":"2018","journal-title":"Nat. Nanotechnol."},{"issue":"7","key":"10.1016\/j.mam.2025.101359_bib147","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41431-018-0132-4","article-title":"Circulating cell-free nucleic acids: characteristics and applications","volume":"26","author":"P\u00f6s","year":"2018","journal-title":"Eur. J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib148","first-page":"181","volume":"23","author":"Potosky","year":"2001","journal-title":"Impact of screening on incidence and mortality of prostate cancer in the United States"},{"issue":"11","key":"10.1016\/j.mam.2025.101359_bib149","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1021\/pr900518v","article-title":"Differential secreted proteome approach in murine model for candidate biomarker discovery in colon cancer","volume":"8","author":"Rangiah","year":"2009","journal-title":"J. Proteome Res."},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib150","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1007\/s00280-010-1430-x","article-title":"Preclinical pharmacokinetic, toxicological and biomarker evaluation of SR16157, a novel dual-acting steroid sulfatase inhibitor and selective estrogen receptor modulator","volume":"67","author":"Rausch","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.mam.2025.101359_bib151","doi-asserted-by":"crossref","first-page":"991","DOI":"10.3390\/ph5090991","article-title":"Applications of cell-penetrating peptides for tumor targeting and future cancer therapies","volume":"5","author":"Regberg","year":"2012","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib153","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.juro.2013.07.001","article-title":"Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer","volume":"190","author":"Ren","year":"2013","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib154","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1471-2407-10-27","article-title":"MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol","volume":"10","author":"Ren","year":"2010","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib155","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1074\/jbc.M209548200","article-title":"Cell-penetrating peptides: a reevaluation of the mechanism of cellular uptake","volume":"278","author":"Richard","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib156","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2012.08.012","article-title":"Transcriptional biomarkers \u2013 high throughput screening, quantitative verification, and bioinformatical validation methods","volume":"59","author":"Riedmaier","year":"2013","journal-title":"Methods"},{"issue":"10","key":"10.1016\/j.mam.2025.101359_bib157","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib158","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.mam.2025.101359_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103690","article-title":"Noncoding RNA as an influential epigenetic modulator with promising roles in cancer therapeutics","volume":"28","author":"Roy","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"10","key":"10.1016\/j.mam.2025.101359_bib160","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1039\/c0an00204f","article-title":"Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer","volume":"135","author":"Rusling","year":"2010","journal-title":"Analyst"},{"issue":"Pt B","key":"10.1016\/j.mam.2025.101359_bib161","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jconrel.2015.09.031","article-title":"Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells","volume":"220","author":"Saari","year":"2015","journal-title":"J Control Release"},{"key":"10.1016\/j.mam.2025.101359_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.114168","article-title":"STAT3 signaling in prostate cancer progression and therapy resistance: an oncogenic pathway with diverse functions","volume":"158","author":"Sadrkhanloo","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib163","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trecan.2015.08.010","article-title":"Long noncoding RNAs in cancer: from function to translation","volume":"1","author":"Sahu","year":"2015","journal-title":"Trends in Cancer"},{"key":"10.1016\/j.mam.2025.101359_bib164","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms16079","article-title":"MicroRNA cluster miR-17-92 regulates multiple functionally related voltage-gated potassium channels in chronic neuropathic pain","volume":"8","author":"Sakai","year":"2017","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.mam.2025.101359_bib165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrc3950","article-title":"Applications of the CRISPR-Cas9 system in cancer biology","volume":"15","author":"S\u00e1nchez-Rivera","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib166","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.mam.2025.101359_bib167","doi-asserted-by":"crossref","first-page":"11391","DOI":"10.1021\/acs.chemrev.9b00153","article-title":"Designer peptide and protein dendrimers: a cross-sectional analysis","volume":"119","author":"Sapra","year":"2019","journal-title":"Chemical reviews"},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib168","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/CCO.0000000000000065","article-title":"Biomarkers in prostate cancer: what's new?","volume":"26","author":"Sartori","year":"2014","journal-title":"Curr. Opin. Oncol."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib169","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.juro.2008.08.119","article-title":"Annexin A3 in urine: a highly specific noninvasive marker for prostate cancer early detection","volume":"181","author":"Schostak","year":"2009","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib170","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nrc3066","article-title":"Cell-free nucleic acids as biomarkers in cancer patients","volume":"11","author":"Schwarzenbach","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib171","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1101\/gr.208652.116","article-title":"The identification and functional annotation of RNA structures conserved in vertebrates","volume":"27","author":"Seemann","year":"2017","journal-title":"Genome Res."},{"key":"10.1016\/j.mam.2025.101359_bib172","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.biochi.2023.07.012","article-title":"Functional implications and therapeutic targeting of androgen response elements in prostate cancer","volume":"214","author":"Senapati","year":"2023","journal-title":"Biochimie"},{"key":"10.1016\/j.mam.2025.101359_bib173","series-title":"RNA Structure and Function","first-page":"371","article-title":"Functional role of non-coding RNAs in prostate cancer: from biomarker to therapeutic targets","author":"Senapati","year":"2023"},{"issue":"24","key":"10.1016\/j.mam.2025.101359_bib174","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1158\/1078-0432.CCR-12-2715","article-title":"Highly specific targeting of the TMPRSS2\/ERG fusion gene using liposomal nanovectors","volume":"18","author":"Shao","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.mam.2025.101359_bib175","first-page":"1362","volume":"vol. 114","author":"Sharova","year":"2016"},{"key":"10.1016\/j.mam.2025.101359_bib176","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2019.10.006","article-title":"Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel","volume":"468","author":"Shen","year":"2020","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib177","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.chembiol.2018.11.012","article-title":"Stabilization of lncRNA GAS5 by a small molecule and its implications in diabetic adipocytes","volume":"26","author":"Shi","year":"2019","journal-title":"Cell Chem. Biol."},{"issue":"13","key":"10.1016\/j.mam.2025.101359_bib178","volume":"8","author":"Singh","year":"2023","journal-title":"Nanomaterials-Based Biosensors for the Detection of Prostate Cancer Biomarkers: Recent Trends and Future Perspective"},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib179","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/nat.2011.0293","article-title":"Polymers in small-interfering RNA delivery","volume":"21","author":"Singha","year":"2011","journal-title":"Nucleic Acid Ther"},{"issue":"9","key":"10.1016\/j.mam.2025.101359_bib180","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","article-title":"Integrating liquid biopsies into the management of cancer","volume":"14","author":"Siravegna","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"42","key":"10.1016\/j.mam.2025.101359_bib181","doi-asserted-by":"crossref","first-page":"6214","DOI":"10.2174\/1381612821666151027153410","article-title":"Synthetic and biological vesicular nano-carriers designed for gene delivery","volume":"21","author":"Soltani","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"21","key":"10.1016\/j.mam.2025.101359_bib182","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1158\/0008-5472.CAN-08-0127","article-title":"Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes","volume":"68","author":"Sonoke","year":"2008","journal-title":"Cancer Res."},{"issue":"7231","key":"10.1016\/j.mam.2025.101359_bib183","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/nature07762","article-title":"Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression","volume":"457","author":"Sreekumar","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib184","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkp841","article-title":"Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents","volume":"38","author":"Stein","year":"2009","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib185","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/nar\/16.8.3209","article-title":"Physicochemical properties of phospborothioate oligodeoxynucleotides","volume":"16","author":"Stein","year":"1988","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib186","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ijc.24778","article-title":"Adeno\u2010associated virus\u2013delivered short hairpin\u2010structured RNA for androgen receptor gene silencing induces tumor eradication of prostate cancer xenografts in nude mice: a preclinical study","volume":"126","author":"Sun","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib187","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1373\/clinchem.2008.108498","article-title":"Multimarker circulating DNA assay for assessing blood of prostate cancer patients","volume":"55","author":"Sunami","year":"2009","journal-title":"Clin. Chem."},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib188","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071637","article-title":"Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer","volume":"8","author":"Sung","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib189","first-page":"1257","volume":"55","author":"Swanson","year":"2006","journal-title":"Quantitative analysis of prostate metabolites using 1H HR-MAS spectroscopy"},{"issue":"4","key":"10.1016\/j.mam.2025.101359_bib190","first-page":"420","article-title":"Modern urology perspectives on prostate cancer biomarkers","volume":"71","author":"Szeliski","year":"2018","journal-title":"Cent European J Urol"},{"issue":"4","key":"10.1016\/j.mam.2025.101359_bib191","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.mam.2025.101359_bib192","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155710","article-title":"CRISPR-mediated silencing of non-coding RNAs: a novel putative treatment for prostate cancer","volume":"264","author":"Tabibian","year":"2024","journal-title":"Pathol. Res. Pract."},{"issue":"17","key":"10.1016\/j.mam.2025.101359_bib193","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1158\/1078-0432.CCR-12-3722","article-title":"Trial designs for personalizing cancer care: a systematic review and classification","volume":"19","author":"Tajik","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.mam.2025.101359_bib194","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1158\/0008-5472.CAN-20-3819","article-title":"Targeting epigenetic and posttranscriptional gene regulation by PSF impairs hormone therapy\u2013refractory cancer growth","volume":"81","author":"Takayama","year":"2021","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.mam.2025.101359_bib195","first-page":"1665","volume":"32","author":"Takayama","year":"2013","journal-title":"Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib196","first-page":"6","volume":"20","author":"Thal","year":"2006","journal-title":"The Role of Biomarkers in Clinical Trials for Alzheimer Disease"},{"issue":"10","key":"10.1016\/j.mam.2025.101359_bib197","doi-asserted-by":"crossref","first-page":"2704s","DOI":"10.1093\/jn\/136.10.2704S","article-title":"PSA: a biomarker for disease. A biomarker for clinical trials. How useful is it?","volume":"136","author":"Thompson","year":"2006","journal-title":"J. Nutr."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib198","article-title":"Non-coding RNAs and potential therapeutic targeting in cancer","volume":"1875","author":"Toden","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib199","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1593\/neo.07822","article-title":"Role of the TMPRSS2-ERG gene fusion in prostate cancer","volume":"10","author":"Tomlins","year":"2008","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.mam.2025.101359_bib200","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.neo.2021.10.003","article-title":"STAT3 as a mediator of oncogenic cellular metabolism: pathogenic and therapeutic implications","volume":"23","author":"To\u0161i\u0107","year":"2021","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib201","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cell.2014.05.049","article-title":"Genome-wide mapping and characterization of Notch-regulated long noncoding RNAs in acute leukemia","volume":"158","author":"Trimarchi","year":"2014","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.mam.2025.101359_bib202","doi-asserted-by":"crossref","first-page":"7223","DOI":"10.1093\/nar\/gkr254","article-title":"Characterization of extracellular circulating microRNA","volume":"39","author":"Turchinovich","year":"2011","journal-title":"Nucleic Acids Res."},{"issue":"11","key":"10.1016\/j.mam.2025.101359_bib203","doi-asserted-by":"crossref","DOI":"10.3390\/cells9112342","article-title":"The PTEN conundrum: how to target PTEN-deficient prostate cancer","volume":"9","author":"Turnham","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib204","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.04.012","article-title":"Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score","volume":"70","author":"Van Neste","year":"2016","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib205","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1021\/acscentsci.7b00009","article-title":"Defining RNA\u2013small molecule affinity landscapes enables design of a small molecule inhibitor of an oncogenic noncoding RNA","volume":"3","author":"Velagapudi","year":"2017","journal-title":"ACS Cent. Sci."},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib206","first-page":"11034","article-title":"Current status of biomarkers for prostate","volume":"14","author":"Velonas","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib207","first-page":"514","article-title":"Cancer immunotherapy, Part 3: challenges and future trends","volume":"42","author":"Ventola","year":"2017","journal-title":"P t"},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib208","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib209","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib210","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1021\/acsomega.9b04150","article-title":"Gold nanoshell-linear tetrapyrrole conjugates for near infrared-activated dual photodynamic and photothermal therapies","volume":"5","author":"Wang","year":"2020","journal-title":"ACS Omega"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib211","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s12943-024-02021-y","article-title":"CRISPR-Cas13d screens identify KILR, a breast cancer risk-associated lncRNA that regulates DNA replication and repair","volume":"23","author":"Wang","year":"2024","journal-title":"Mol. Cancer"},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib212","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib213","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/nprot.2006.249","article-title":"Selective 2'-hydroxyl acylation analyzed by primer extension (SHAPE): quantitative RNA structure analysis at single nucleotide resolution","volume":"1","author":"Wilkinson","year":"2006","journal-title":"Nat. Protoc."},{"issue":"5","key":"10.1016\/j.mam.2025.101359_bib214","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cell.2008.10.012","article-title":"3\u2032 end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA","volume":"135","author":"Wilusz","year":"2008","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.mam.2025.101359_bib215","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","article-title":"Noncoding RNA therapeutics - challenges and potential solutions","volume":"20","author":"Winkle","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9","key":"10.1016\/j.mam.2025.101359_bib216","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41570-020-0201-4","article-title":"Inhibition of RNA-binding proteins with small molecules","volume":"4","author":"Wu","year":"2020","journal-title":"Nat. Rev. Chem"},{"issue":"12","key":"10.1016\/j.mam.2025.101359_bib217","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx118","article-title":"Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer","volume":"109","author":"Wyatt","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.mam.2025.101359_bib218","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.biopha.2017.10.037","article-title":"MiR-129 inhibits cell proliferation and metastasis by targeting ETS1 via PI3K\/AKT\/mTOR pathway in prostate cancer","volume":"96","author":"Xu","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.mam.2025.101359_bib219","doi-asserted-by":"crossref","DOI":"10.1016\/j.susmat.2019.e00109","article-title":"Gold nanoparticle based photothermal therapy: development and application for effective cancer treatment","volume":"22","author":"Yang","year":"2019","journal-title":"Sustainable Materials and Technologies"},{"key":"10.1016\/j.mam.2025.101359_bib220","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jconrel.2019.07.021","article-title":"New insight into isolation, identification techniques and medical applications of exosomes","volume":"308","author":"Yang","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.mam.2025.101359_bib221","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jconrel.2016.04.034","article-title":"Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy","volume":"232","author":"Yao","year":"2016","journal-title":"J Control Release"},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib222","first-page":"326","volume":"32","author":"Zen","year":"2012","journal-title":"Circulating MicroRNAs: a novel class of biomarkers to diagnose and monitor human cancers"},{"issue":"11","key":"10.1016\/j.mam.2025.101359_bib223","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib224","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.canlet.2016.03.003","article-title":"Long non-coding RNA: a newly deciphered \u201ccode\u201d in prostate cancer","volume":"375","author":"Zhang","year":"2016","journal-title":"Cancer Lett."},{"issue":"9","key":"10.1016\/j.mam.2025.101359_bib225","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkad197","article-title":"BESST: a novel LncRNA knockout strategy with less genome perturbance","volume":"51","author":"Zhang","year":"2023","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.mam.2025.101359_bib226","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2015.05.003","article-title":"A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA","volume":"365","author":"Zhang","year":"2015","journal-title":"Cancer letters"},{"issue":"6","key":"10.1016\/j.mam.2025.101359_bib227","first-page":"939","volume":"40","author":"Zhao","year":"2010","journal-title":"Genome-wide identification of polycomb-associated RNAs by RIP-seq"},{"issue":"1","key":"10.1016\/j.mam.2025.101359_bib228","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13045-022-01230-6","article-title":"Designing strategies of small-molecule compounds for modulating non-coding RNAs in cancer therapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.mam.2025.101359_bib229","first-page":"287","article-title":"TGF-\u03b2 signaling and androgen receptor status determine apoptotic cross-talk in human","volume":"68","author":"Zhu","year":"2008","journal-title":"prostate cancer cells"}],"container-title":["Molecular Aspects of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299725000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0098299725000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T04:42:52Z","timestamp":1748407372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299725000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":228,"alternative-id":["S0098299725000238"],"URL":"https:\/\/doi.org\/10.1016\/j.mam.2025.101359","relation":{},"ISSN":["0098-2997"],"issn-type":[{"value":"0098-2997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting and engineering biomarkers for prostate cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Aspects of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mam.2025.101359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101359"}}